With falling R&D productivity and continued healthcare cost containment and generic competition pushing down the returns available for successfully launched products, only those companies able to complement internal efforts with a strong partnering strategy will be able to remain competitive over the next five-to-ten years. Pharmaceutical licensing strategies: Best practices in deal-making, valuations and strategic management provides a detailed analysis of licensing strategies in the pharmaceutical and biotechnology industries. The report draws upon deal-making trend data, primary research survey results and a profile of best practices in pharmaceutical licensing in order to present a set of actionable recommendations for optimizing deal-making.